Prothena Corporation PLC (PRTA) to Release Earnings on Monday
Prothena Corporation PLC (NASDAQ:PRTA) will post its quarterly earnings results after the market closes on Monday, October 30th. Analysts expect Prothena Corporation PLC to post earnings of ($1.41) per share for the quarter.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.43. The business had revenue of $26.81 million for the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business’s quarterly revenue was up 7951.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.18) earnings per share. On average, analysts expect Prothena Corporation PLC to post $-4.43 EPS for the current fiscal year and $-5.03 EPS for the next fiscal year.
Shares of Prothena Corporation PLC (PRTA) traded up 0.74% during mid-day trading on Monday, hitting $58.34. 25,784 shares of the stock traded hands. The stock’s market cap is $2.23 billion. The firm’s 50 day moving average price is $62.65 and its 200-day moving average price is $57.71. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $70.00.
Several research firms have recently commented on PRTA. Deutsche Bank AG set a $73.00 price target on shares of Prothena Corporation PLC and gave the stock a “buy” rating in a research report on Monday. ValuEngine lowered shares of Prothena Corporation PLC from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $100.00 target price on shares of Prothena Corporation PLC in a research report on Monday, October 2nd. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $75.00 target price on shares of Prothena Corporation PLC in a research report on Monday, October 2nd. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of Prothena Corporation PLC in a research report on Friday, September 29th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $78.58.
In other Prothena Corporation PLC news, insider Tara Nickerson sold 17,500 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the transaction, the insider now owns 19,500 shares in the company, valued at $1,240,200. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total value of $224,595.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,424 shares of company stock worth $1,922,787. Corporate insiders own 3.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Prothena Corporation PLC (PRTA) to Release Earnings on Monday” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/23/prothena-corporation-plc-prta-to-release-earnings-on-monday.html.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.